Cellebrite DI (CLBT) Scheduled to Post Quarterly Earnings on Wednesday

Cellebrite DI (NASDAQ:CLBT - Get Free Report) will release its earnings data before the market opens on Wednesday, November 6th. Analysts expect Cellebrite DI to post earnings of $0.11 per share for the quarter. Cellebrite DI has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Persons interested in participating in the company's earnings conference call can do so using this link.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, August 15th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.02. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. The business had revenue of $95.70 million during the quarter, compared to the consensus estimate of $91.94 million. During the same quarter last year, the firm earned $0.05 earnings per share. The firm's quarterly revenue was up 24.8% compared to the same quarter last year. On average, analysts expect Cellebrite DI to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cellebrite DI Trading Down 0.6 %

Shares of CLBT stock traded down $0.12 on Wednesday, reaching $18.36. 422,391 shares of the company's stock were exchanged, compared to its average volume of 1,121,658. The company's fifty day simple moving average is $17.35 and its 200 day simple moving average is $13.88. The stock has a market capitalization of $3.78 billion, a PE ratio of -34.64, a P/E/G ratio of 2.52 and a beta of 1.52. Cellebrite DI has a 52 week low of $6.55 and a 52 week high of $18.75.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Needham & Company LLC lifted their price objective on shares of Cellebrite DI from $14.00 to $17.00 and gave the company a "buy" rating in a report on Friday, August 16th. Craig Hallum raised their price objective on Cellebrite DI from $20.00 to $23.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. Deutsche Bank Aktiengesellschaft upped their target price on Cellebrite DI from $15.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, August 16th. JPMorgan Chase & Co. lifted their price objective on Cellebrite DI from $14.00 to $15.00 and gave the company an "overweight" rating in a report on Wednesday, August 14th. Finally, Bank of America raised their target price on shares of Cellebrite DI from $13.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, August 16th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $18.57.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.